Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes

@article{Barton2005Interleukin6AN,
  title={Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes},
  author={B. Barton},
  journal={Expert Opinion on Therapeutic Targets},
  year={2005},
  volume={9},
  pages={737 - 752}
}
  • B. Barton
  • Published 2005
  • Medicine
  • Expert Opinion on Therapeutic Targets
  • Interleukin-6 (IL-6) is a pleiomorphic cytokine whose growth factor properties play an important role in the development and progression of many types of cancer. IL-6 is produced in response to a variety of stimuli, and is required for the development of T and B lymphocytes to effector cells. In certain neoplasias, such as multiple myeloma, IL-6 is both produced and required for survival by the cancer cell itself. In other neoplasias, IL-6 may come from tissue surrounding the tumour. Thus… CONTINUE READING
    70 Citations
    Interleukin-6 in oral diseases: a review.
    • 107
    Interleukin-6 in aging and chronic disease: a magnificent pathway.
    • 436
    • PDF
    Production of cachexia mediators by Walker 256 cells from ascitic tumors
    • 23
    STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance
    • B. Barton
    • Biology, Medicine
    • Expert opinion on therapeutic targets
    • 2006
    • 32

    References

    SHOWING 1-10 OF 222 REFERENCES
    Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias.
    • T. Hirano
    • Biology, Medicine
    • International journal of cell cloning
    • 1991
    • 95
    Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
    • 474
    • PDF
    Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    • 60
    • PDF
    Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1
    • 17
    Interleukin 6 is essential for in vivo development of B lineage neoplasms
    • 226
    • PDF
    Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
    • 68
    • PDF
    Interleukin-6 immunoreactivity in human tumors.
    • 143
    Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen.
    • 45